Facebook Pixel {العنوان: سلسلة} | {اسم المغناطيس: سلسلة} - {الفئة: سلسلة} - اقرأ هذه القصة على Magzter.com
استمتع بـUnlimited مع Magzter GOLD

استمتع بـUnlimited مع Magzter GOLD

احصل على وصول غير محدود إلى أكثر من 9000 مجلة وصحيفة وقصة مميزة مقابل

$149.99
 
$74.99/سنة

يحاول ذهب - حر

Necessary evil or strategic asset?

February 11, 2025

|

Financial Express Hyderabad

BY REIMAGINING ITSELF, HR CAN RECLAIM REPUTATION & BE AT THE CORE OF OUR ECONOMIC ASPIRATIONS

- M MUNEER

The recent endorsement of renaming the ministry of human resource development (HRD) to the ministry of education in India reignites long-standing debates about the relevance and reputation of human resources (HR). This shift seems symbolic of the broader skepticism surrounding HR's role, mostly caricatured as bureaucratic, inefficient, and excessively self-serving.

Yet, in a country poised to become the world's third-largest economy, the debate isn't whether HR is necessary but rather how it can be reimagined to drive growth, inclusivity, and strategic transformation.

HR has long been the favorite target of workplace grievances. Over two decades ago, Fortune editor Tom Stewart provocatively argued HR should be "abolished" rather than improved. Fast forward to today, and similar criticisms persist globally, albeit in more nuanced forms. HR is accused of being excessively process-oriented, resistant to innovation, and more aligned with corporate compliance than employee advocacy. Several surveys reveal only about 40% of Indian employees believed HR genuinely addressed their concerns.

One of the most glaring examples of this skepticism emerged in 2019 when The Atlantic highlighted HR's failure to address workplace sexual harassment adequately. Critics pointed out how HR departments keep protecting the organization's reputation over safeguarding employees. This concern is not theoretical—India's own history, such as the handling of harassment allegations against high-profile figures, reflects systemic flaws in workplace grievance mechanisms.

المزيد من القصص من Financial Express Hyderabad

Financial Express Hyderabad

US deal alone can’t ease global turmoil: FM

SHEADDED THAT

time to read

1 mins

February 24, 2026

Financial Express Hyderabad

US-based The Cheesecake Factory enters India

THE CHEESECAKE FACTORY

time to read

1 min

February 24, 2026

Financial Express Hyderabad

Fraud impact likely to be limited: IDFC First

EMPLOYEES SUSPENDED; KPMG TO DO FORENSIC AUDIT

time to read

2 mins

February 24, 2026

Financial Express Hyderabad

Bitcoin slides below $65K amid tariff woes

BITCOIN BRIEFLY SLID below $65,000 on Monday for the second time this month, roiled by uncertainty over the status of US tariffs.

time to read

1 min

February 24, 2026

Financial Express Hyderabad

GDP likely grew 7.35% in Q3: FE poll

INDIA'S ECONOMY LIKELY recorded a growth rate of around 7.35% in the October-December quarter (Q3) of FY26, according to a Financial Express poll of economists.

time to read

2 mins

February 24, 2026

Financial Express Hyderabad

Lenskart to focus on margin-led growth

ANTICIPATES 25% REVENUE, 53% EBITDA CAGR DURING FY25-28

time to read

1 mins

February 24, 2026

Financial Express Hyderabad

Renault to take full control of Flexis

RENAULT WILL BUY out truckmaker Volvo Group’s and shipping firm CMA CGM’s stakes in their new-generation electric vans joint venture Flexis, the French carmaker said on Monday.

time to read

1 min

February 24, 2026

Financial Express Hyderabad

ABB India upbeat on capex

THE FIRM’S ELECTRIFICATION SEGMENT SEES A RISE IN EXPORT REVENUES

time to read

2 mins

February 24, 2026

Financial Express Hyderabad

Over-disclosures as problematic as non-disclosures: Sebi WTM

WHEN KEY RISKS of a company are buried in dense and vaguely-framed documents, over-disclosures can be as problematic as non-disclosures, Sebi Whole Time Member Amarjeet Singh said on Monday.

time to read

1 min

February 24, 2026

Financial Express Hyderabad

Centre reopens PLI scheme for key bulk drugs

THE GOVERNMENT HAS reopened applications under the performance-linked incentive (PLI) scheme for the production of two critical bulk drugs: the broad-spectrum antibiotic meropenem and the antiretroviral medicine ritonavir.

time to read

1 min

February 24, 2026

Listen

Translate

Share

-
+

Change font size